PAM
AXSM icon

PVG Asset Management’s Axsome Therapeutics AXSM Stock Holding History

PVG Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14,240
Closed -$45K – 83
2018
Q2 		$45K Hold
14,240
– – 0.03% 93
2018
Q1 		$34.9K Buy
+14,240
New +$42.6K 0.02% 93
2017
Q4 		– Sell
-18,725
Closed -$104K – 79
2017
Q3 		$104K Sell
18,725
-1,870
-9% -$10K 0.05% 73
2017
Q2 		$113K Hold
20,595
– – 0.04% 63
2017
Q1 		$80.3K Buy
+20,595
New +$98.4K 0.02% 88

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PVG Asset Management's AXSM Position: Q3 2018 in Review

PVG Asset Management sold out of Axsome Therapeutics (AXSM) in Q3 2018, closing a stake of 14,240 shares — an estimated $45K sold.

PVG Asset Management first reported a position in AXSM in Q1 2017 and held it in 5 quarters. The position peaked at $113K in Q2 2017. 35 funds tracked by Wall St. Rank hold AXSM as of Q3 2018.

  • PVG Asset Management reported no remaining Axsome Therapeutics position as of Q3 2018 after selling out during the quarter.
  • PVG Asset Management sold 14,240 Axsome Therapeutics shares in Q3 2018, an estimated $45K.
  • PVG Asset Management first reported a position in Axsome Therapeutics in Q1 2017 and held it in 5 quarters.
  • PVG Asset Management's Axsome Therapeutics position peaked at $113K in Q2 2017.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2018.

Based on PVG Asset Management's 13F filing for Q3 2018, filed 15 Nov 2018.